Internal Medicine, Pulmonary Disease · Springfield, IL
NPI
1083820757
Since 2007
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
1025 S 6th St
Springfield, IL, 62703
Phone (217) 528-7541
Groups this clinician bills Medicare through
Medicare paid, 2024
$273K
7,485 services
Medicare patients, 2024
815
Average age 73
Drug cost, 2024
$2.7M
6,308 prescriptions
Company payments, 2025
$1,317
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Gaurav Sangwan was code 94618 (pulmonary function testing), 644 times for 494 patients. In total Gaurav Sangwan billed 7,485 services in 37 codes, and Medicare paid $273K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-05-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 94618 Pulmonary Function Testing | Office | 644 | 494 | $20.73 | $13K |
| 94375 Pulmonary Function Testing | Office | 630 | 484 | $23.38 | $15K |
| 99214 Office E&M - Established | Office | 414 | 344 | $92.17 | $38K |
| 99215 Office E&M - Established | Office | 205 | 149 | $131.86 | $27K |
| 94060 Pulmonary Function Testing | Office | 188 | 154 | $26.25 | $4,936 |
| 95810 Sleep Study | Office | 102 | 51 | $219.20 | $22K |
| 95811 Sleep Study | Office | 101 | 49 | $233.46 | $24K |
| 99204 Office E&M - New | Office | 99 | 99 | $112.81 | $11K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 70 | 65 | $13.04 | $913 |
| 94726 Pulmonary Function Testing | Office | 52 | 48 | $40.65 | $2,114 |
| 94729 Pulmonary Function Testing | Office | 52 | 48 | $39.59 | $2,059 |
| J7613 Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | Office | 46 | 16 | $0.03 | $1.23 |
| 94729 Pulmonary Function Testing | Facility | 45 | 45 | $6.09 | $274 |
| 94726 Pulmonary Function Testing | Facility | 45 | 45 | $8.15 | $367 |
| 95810 Sleep Study | Facility | 38 | 37 | $83.73 | $3,182 |
By year: 2022 $272K for 4,522 services; 2023 $271K for 5,277 services; 2024 $273K for 7,485 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 30 | 27 | $8.37 | $251 |
| 87635 COVID Specific | 18 | 18 | $50.28 | $905 |
Medicare prescription drug claims, 2024
In 2024, the drug Gaurav Sangwan prescribed most often to Medicare patients was Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter), with 1,618 prescriptions and refills. In total Gaurav Sangwan wrote 6,308 Medicare prescriptions that cost $2.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 1,618 | 2,034 | 267 | $1.3M |
| Montelukast Sodium Generic | 745 | 1,570 | 178 | $6,056 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 691 | 741 | 276 | $17K |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | 374 | 457 | 80 | $266K |
| Prednisone Generic | 319 | 333 | 171 | $750 |
| Breo Ellipta Fluticasone/Vilanterol | 221 | 277 | 41 | $105K |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | 219 | 282 | 46 | $128K |
| Incruse Ellipta Umeclidinium Bromide | 197 | 235 | 35 | $80K |
| Spiriva Respimat Tiotropium Bromide | 194 | 238 | 48 | $124K |
| Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate | 190 | 231 | 40 | $36K |
| Azithromycin Generic | 176 | 230 | 79 | $671 |
| Arnuity Ellipta Fluticasone Furoate | 171 | 231 | 34 | $49K |
| Stiolto Respimat Tiotropium Br/Olodaterol Hcl | 152 | 182 | 28 | $87K |
| Ventolin Hfa Albuterol Sulfate | 115 | 121 | 46 | $6,720 |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 112 | 146 | 27 | $13K |
Brand drugs: 4,298 claims; generic drugs: 2,010 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Gaurav Sangwan $1,317 ($1,317 in general payments such as food, travel and fees) from 13 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $348.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 10 | $348 |
| Inspire Medical Systems, Inc. INSP | 11 | $306 |
| GlaxoSmithKline, LLC. GSK | 25 | $180 |
| Novo Nordisk Inc NVO | 1 | $117 |
| CVRx, Inc. CVRX | 1 | $80.32 |
| Regeneron Healthcare Solutions, Inc. REGN | 3 | $61.08 |
| Axsome Therapeutics, Inc. AXSM | 3 | $48.71 |
| Amgen Inc. AMGN | 2 | $41.23 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 1 | $36.98 |
| Viatris Specialty LLC | 2 | $33.67 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.